Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 4:55 PM ET


Company Overview of Boehringer Ingelheim Limited

Company Overview

Boehringer Ingelheim Limited is engaged in the research, development, and manufacture of prescription medicines, over-the-counter, and animal healthcare products in the United Kingdom. It focuses on various medical conditions, such as respiratory, cardiology, virology, central nervous system, and cerebrovascular. The company offers prescription medicines for the treatment of chronic obstructive pulmonary disease, heart attack, secondary stroke prevention and treatment, high blood pressure, thromboembolic disease, HIV/AIDS, Parkinson's disease, arthritis, and pain relief in cancer. It offers consumer healthcare products in the areas of constipation, antispasmodics, stool softeners, vitamins a...

Ellesfield Avenue

Bracknell,  RG12 8YS

United Kingdom

Founded in 1955


44 13 4442 4600


44 13 4474 1444

Key Executives for Boehringer Ingelheim Limited

Managing Director
Finance & Administration Director
Senior Vice President of Global Biopharma Operations
Head of Established Markets
Compensation as of Fiscal Year 2015.

Boehringer Ingelheim Limited Key Developments

Boehringer Ingelheim Ltd Wins GBP 567.5 Million Multiple Awardees Contract for Pharmaceutical Products

Boehringer Ingelheim Ltd. won a GBP 567.5 million (excluding VAT) multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for pharmaceutical products (Contract Award Notice No.: 2016/S 023-036546).

Boehringer Ingelheim Limited Presents at IMPACT 2015 Capital Conference, Nov-04-2015 10:45 AM

Boehringer Ingelheim Limited Presents at IMPACT 2015 Capital Conference, Nov-04-2015 10:45 AM. Venue: The Ritz-Carlton Hotel, Philadelphia, Pennsylvania, United States. Speakers: Larry Brooks, Director, Business Innovation ­ Digital Health.

Boehringer Ingelheim’s Investigational Biologic Cleared Skin Better, Faster and for Longer Than Ustekinumab in Phase II Psoriasis Study

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066, over ustekinumab. After 9 months, 69% of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30% of patients on ustekinumab.1 Patients also achieved this skin clearance significantly faster (approximately 8 weeks versus approximately 16 weeks) and for more than two months longer (= 32 weeks versus 24 weeks) than those on ustekinumab. In addition, completely clear skin (PASI 100) was maintained after 9 months in nearly triple the percentage of patients on BI 655066 compared with ustekinumab (43% versus 15%). These 24-week findings from a Phase II study in psoriasis were presented in an oral presentation by Dr. Kim A. Papp at the 24th European Academy of Dermatology and Venereology (EADV) congress in Copenhagen. The study (NCT02054481 [2]) investigated the efficacy and safety of BI 655066 versus ustekinumab in 166 patients. These data build on Phase II data presented earlier this year at the Annual Meeting of the American Academy of Dermatology (AAD). Primary endpoint results showed nearly double the percentage of patients with moderate-to-severe plaque psoriasis achieved clear or almost clear skin (PASI 90) after 12 weeks of treatment with BI 655066, compared to ustekinumab (77.1% versus 40% of patients). The new data further demonstrate that BI 655066 has similar safety and tolerability to ustekinumab, regardless of dose, with no serious drug-related side-effects.1 The most common side effects were runny nose, sore throat, and headache. The data represent results for BI 655066 180mg (n=42) injection under the skin, delivered at weeks 0, 4 and 16. The BI 655066 90mg (n=41) dose also showed superior efficacy, onset and duration of action over ustekinumab after 9 months. More patients with moderate-to-severe psoriasis maintained almost clear skin (PASI 90) with BI 655066 compared to those on ustekinumab (81% vs. 30%). More patients on BI 655066 had completely clear skin (PASI 100) compared with ustekinumab (54% vs. 15%). An exploratory single dose of BI 655066 18mg (n=43) was also studied. 1 ustekinumab 45mg/90mg (n=40) was delivered as an injection under the skin at weeks 0, 4 and 16.

Similar Private Companies By Industry

Company Name Region
Exeter Antioxidant Therapeutics Ltd. Europe
AccentBio Ltd. Europe
Miro Omega-3 Limited Europe
Alliance Boots Services Ltd. Europe
Teva UK Ltd Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Boehringer Ingelheim Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at